Evofem Q1 net income $1.0M, revenue $0.8M; plans 55-60% PHEXXI COGS cut

Evofem Biosciences, Inc.

2025-Q1 EPS reported $0.00 revenue$845,000

Net sales $0.8M, down 78% from $3.6M YoY due to order timing after Q4 2024 stocking.
Net income $1.0M ($0.01 basic EPS) vs net loss $4.9M ($0.16 loss) in Q1 2024.
Partnered with Windtree to reduce PHEXXI manufacturing cost by 55-60%; Evofem bears no tech transfer costs.
Received $1.5M in April from sale of notes/warrants to Aditxt under merger agreement.
Cash and restricted cash $1.1M at March 31, 2025; new U.S. patent for SOLOSEC extends to 2040.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.